Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for REGENXBIO Inc. (RGNX : NSDQ)
 
 • Company Description   
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.

Number of Employees: 372

 
 • Price / Volume Information   
Yesterday's Closing Price: $20.67 Daily Weekly Monthly
20 Day Moving Average: 432,470 shares
Shares Outstanding: 43.13 (millions)
Market Capitalization: $891.58 (millions)
Beta: 1.12
52 Week High: $46.46
52 Week Low: $19.07
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.79% -23.07%
12 Week -16.04% -8.90%
Year To Date -36.79% -24.83%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9804 MEDICAL CENTER DRIVE
-
ROCKVILLE,MD 20850
USA
ph: 240-552-8181
fax: -
ir@regenxbio.com http://www.regenxbio.com
 
 • General Corporate Information   
Officers
Kenneth T. Mills - President; Chief Executive Officer and Director
Allan M. Fox - Chairman of the Board of Directors
Vittal Vasista - Chief Financial Officer
Daniel J. Abdun-Nabi - Director
Jean Bennett - Director

Peer Information
REGENXBIO Inc. (CORR.)
REGENXBIO Inc. (RSPI)
REGENXBIO Inc. (CGXP)
REGENXBIO Inc. (BGEN)
REGENXBIO Inc. (GTBP)
REGENXBIO Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75901B107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 43.13
Most Recent Split Date: (:1)
Beta: 1.12
Market Capitalization: $891.58 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.57 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.47 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 11.81% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 8.91
PEG Ratio: -
Price Ratios
Price/Book: 1.29
Price/Cash Flow: 6.17
Price / Sales: 1.88
EPS Growth
vs. Year Ago Period: -35.00%
vs. Previous Quarter: -124.29%
Sales Growth
vs. Year Ago Period: 17.66%
vs. Previous Quarter: -94.43%
ROE
03/31/22 - 17.92
12/31/21 - 22.35
09/30/21 - -44.70
ROA
03/31/22 - 11.50
12/31/21 - 14.09
09/30/21 - -26.35
Current Ratio
03/31/22 - 3.73
12/31/21 - 3.98
09/30/21 - 3.84
Quick Ratio
03/31/22 - 3.73
12/31/21 - 3.98
09/30/21 - 3.84
Operating Margin
03/31/22 - 22.91
12/31/21 - 27.18
09/30/21 - -228.08
Net Margin
03/31/22 - 21.38
12/31/21 - 27.18
09/30/21 - -228.08
Pre-Tax Margin
03/31/22 - 24.20
12/31/21 - 30.03
09/30/21 - -221.91
Book Value
03/31/22 - 15.99
12/31/21 - 17.87
09/30/21 - 10.79
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©